Evidence map›Paper›PMID 37122338›Full record

ReviewFrontiers in medicine2023

Immunotherapies against human bacterial and fungal infectious diseases: A review.

Hafsa Qadri, Abdul Haseeb Shah, Mustfa Alkhanani, Abdullah Almilaibary, Manzoor Ahmad Mir

RetractedOpen access · goldAbstract readReviewRetracted Publication
In one paragraph

Review in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Promising immunotherapeutic targets for treating candidiasis.Frontiers in cellular and infection microbiology · 2024
    Review
  13. Candida albicans and Antifungal Peptides.Infectious diseases and therapy · 2023
    Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Hafsa QadriDepartment of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar, Jammu and Kashmir, India.
Abdul Haseeb ShahDepartment of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar, Jammu and Kashmir, India.
Mustfa AlkhananiDepartment of Biology, College of Sciences, University of Hafr Al Batin, Hafar Al Batin, Saudi Arabia.
Abdullah AlmilaibaryDepartment of Family and Community Medicine, Faculty of Medicine, Al Baha University, Al Baha, Saudi Arabia.
Manzoor Ahmad MirDepartment of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar, Jammu and Kashmir, India.
University of Kashmir · INAl Baha University · SAUniversity of Hafr Al-Batin · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nations' ongoing struggles with a number of novel and reemerging infectious diseases, including the ongoing global health issue, the SARS-Co-V2 (severe acute respiratory syndrome coronavirus 2) outbreak, serve as proof that infectious diseases constitute a serious threat to the global public health. Moreover, the fatality rate in humans is rising as a result of the development of severe infectious diseases brought about by multiple drug-tolerant pathogenic microorganisms. The widespread use of traditional antimicrobial drugs, immunosuppressive medications, and other related factors led to the establishment of such drug resistant pathogenic microbial species. To overcome the difficulties commonly encountered by current infectious disease management and control processes, like inadequate effectiveness, toxicities, and the evolution of drug tolerance, new treatment solutions are required. Fortunately, immunotherapies already hold great potential for reducing these restrictions while simultaneously expanding the boundaries of healthcare and medicine, as shown by the latest discoveries and the success of drugs including monoclonal antibodies (MAbs), vaccinations, etc. Immunotherapies comprise methods for treating diseases that specifically target or affect the body's immune system and such immunological procedures/therapies strengthen the host's defenses to fight those infections. The immunotherapy-based treatments control the host's innate and adaptive immune responses, which are effective in treating different pathogenic microbial infections. As a result, diverse immunotherapeutic strategies are being researched more and more as alternative treatments for infectious diseases, leading to substantial improvements in our comprehension of the associations between pathogens and host immune system. In this review we will explore different immunotherapies and their usage for the assistance of a broad spectrum of infectious ailments caused by various human bacterial and fungal pathogenic microbes. We will discuss about the recent developments in the therapeutics against the growing human pathogenic microbial diseases and focus on the present and future of using immunotherapies to overcome these diseases. Graphical AbstractThe graphical abstract shows the therapeutic potential of different types of immunotherapies like vaccines, monoclonal antibodies-based therapies, etc., against different kinds of human Bacterial and Fungal microbial infections.

Indexed as

Antimicrobial Resistancecytokineshuman bacterial pathogenshuman fungal pathogensimmunotherapymonoclonal antibodiesSARS-CoV-2vaccine

Identifiers

PMID37122338
PMCPMC10140573
OpenAlexW4366090339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.